Graphite Bio Stock Current Valuation
| GRPHDelisted Stock | USD 2.67 0.05 1.84% |
Valuation analysis of Graphite Bio helps investors to measure Graphite Bio's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Graphite Bio's price fluctuation is very steady at this time. Calculation of the real value of Graphite Bio is based on 3 months time horizon. Increasing Graphite Bio's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Graphite Bio is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Graphite Stock. However, Graphite Bio's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.67 | Real 2.4 | Hype 2.67 | Naive 2.83 |
The intrinsic value of Graphite Bio's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Graphite Bio's stock price.
Estimating the potential upside or downside of Graphite Bio helps investors to forecast how Graphite stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Graphite Bio more accurately as focusing exclusively on Graphite Bio's fundamentals will not take into account other important factors: Graphite Bio Company Current Valuation Analysis
Graphite Bio's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Graphite Bio Current Valuation | 1.88 M |
Most of Graphite Bio's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Graphite Bio is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Graphite Bio has a Current Valuation of 1.88 M. This is 99.99% lower than that of the Biotechnology sector and 99.96% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.99% higher than that of the company.
Graphite Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Graphite Bio's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Graphite Bio could also be used in its relative valuation, which is a method of valuing Graphite Bio by comparing valuation metrics of similar companies.Graphite Bio is currently under evaluation in current valuation category among its peers.
Graphite Fundamentals
| Return On Equity | -0.52 | |||
| Return On Asset | -0.18 | |||
| Current Valuation | 1.88 M | |||
| Shares Outstanding | 58.24 M | |||
| Shares Owned By Insiders | 9.17 % | |||
| Shares Owned By Institutions | 84.40 % | |||
| Number Of Shares Shorted | 704.04 K | |||
| Price To Earning | 0.70 X | |||
| Price To Book | 1.01 X | |||
| EBITDA | (70.7 M) | |||
| Net Income | (124.65 M) | |||
| Cash And Equivalents | 322.29 M | |||
| Cash Per Share | 5.54 X | |||
| Total Debt | 362 K | |||
| Debt To Equity | 0.02 % | |||
| Current Ratio | 27.07 X | |||
| Book Value Per Share | 3.17 X | |||
| Cash Flow From Operations | (90.01 M) | |||
| Short Ratio | 7.93 X | |||
| Earnings Per Share | (2.19) X | |||
| Price To Earnings To Growth | (0.08) X | |||
| Target Price | 7.0 | |||
| Beta | 0.2 | |||
| Market Capitalization | 189.84 M | |||
| Total Asset | 188.46 M | |||
| Retained Earnings | (367.05 M) | |||
| Working Capital | 183.22 M | |||
| Current Asset | 8 K | |||
| Current Liabilities | 451 K | |||
| Annual Yield | 0.30 % | |||
| Net Asset | 188.46 M |
About Graphite Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Graphite Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Graphite Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Graphite Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Other Consideration for investing in Graphite Stock
If you are still planning to invest in Graphite Bio check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Graphite Bio's history and understand the potential risks before investing.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |